Serum sodium and survival benefit of liver transplantation

Liver Transplantation

Volumn 21, Issue 3, 2015, Pages 308-313

  Sharma, Pratima ^a   Schaubel, Douglas E ^b   Goodrich, Nathan P ^c   Merion, Robert M ^b,c  

^a UNIVERSITY OF MICHIGAN   (United States)

^b UNIVERSITY OF MICHIGAN   (United States)

^c ARBOR RESEARCH COLLABORATIVE FOR HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALBUMIN; BILIRUBIN; CREATININE; SODIUM; BIOLOGICAL MARKER;

ADULT; ALBUMIN BLOOD LEVEL; ARTICLE; BILIRUBIN BLOOD LEVEL; CAUCASIAN; CHOLESTASIS; CORRELATIONAL STUDY; CREATININE BLOOD LEVEL; FEMALE; GRAFT RECIPIENT; HEPATITIS C; HOSPITAL ADMISSION; HUMAN; HYPONATREMIA; INTERNATIONAL NORMALIZED RATIO; LIVER CIRRHOSIS; LIVER TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; MODEL FOR END STAGE LIVER DISEASE SCORE; PREOPERATIVE PERIOD; PRIORITY JOURNAL; RENAL REPLACEMENT THERAPY; SODIUM BLOOD LEVEL; SURGICAL MORTALITY; SURVIVAL; ADVERSE EFFECTS; BLOOD; DECISION SUPPORT SYSTEM; END STAGE LIVER DISEASE; MIDDLE AGED; MORTALITY; PATIENT SELECTION; PREDICTIVE VALUE; PROPORTIONAL HAZARDS MODEL; REGISTER; RISK FACTOR; TIME; TRANSPLANTATION; TREATMENT OUTCOME; UNITED STATES;

ADULT; BIOMARKERS; DECISION SUPPORT TECHNIQUES; END STAGE LIVER DISEASE; FEMALE; HUMANS; HYPONATREMIA; LIVER TRANSPLANTATION; MALE; MIDDLE AGED; PATIENT SELECTION; PREDICTIVE VALUE OF TESTS; PROPORTIONAL HAZARDS MODELS; REGISTRIES; RISK FACTORS; SODIUM; TIME FACTORS; TISSUE AND ORGAN PROCUREMENT; TREATMENT OUTCOME; UNITED STATES; WAITING LISTS;

EID: 84923700059     PISSN: 15276465     EISSN: 15276473     Source Type: Journal    
DOI: 10.1002/lt.24063     Document Type: Article

References (23)

1. Analysis of waiting times. In: Institute of Medicine. Organ Procurement and Transplantation: Assessing Current Policies and the Potential Impact of the DHHS Final Rule. Washington, DC: National Academies Press; 1999:61-90.
2. Wiesner RH, McDiarmid SV, Kamath PS, Edwards EB, Malinchoc M, Kremers WK, et al. MELD and PELD: application of survival models to liver allocation. Liver Transpl 2001;7:567-580.
3. Wiesner R, Edwards E, Freeman R, Harper A, Kim R, Kamath P, et al.; for United Network for Organ Sharing Liver Disease Severity Score Committee. Model for End-Stage Liver Disease (MELD) and allocation of donor livers. Gastroenterology 2003;124:91-96.
4. Kamath PS, Wiesner RH, Malinchoc M, Kremers W, Therneau TM, Kosberg CL, et al. A model to predict survival in patients with end-stage liver disease. Hepatology 2001;33:464-470.
5. Organ Procurement and Transplantation Network. Policy 9: allocation of livers and liver-intestines. http://optn. transplant.hrsa.gov/ContentDocuments/OPTN-Policies. pdf. Accessed November 2014.
6. Merion RM, Schaubel DE, Dykstra DM, Freeman RB, Port FK, Wolfe RA. The survival benefit of liver transplantation. Am J Transplant 2005;5:307-313.
7. Biggins SW, Kim WR, Terrault NA, Saab S, Balan V, Schiano T, et al. Evidence-based incorporation of serum sodium concentration into MELD. Gastroenterology 2006;130:1652-1660.
8. Kim WR, Biggins SW, Kremers WK, Wiesner RH, Kamath PS, Benson JT, et al. Hyponatremia and mortality among patients on the liver-transplant waiting list. N Engl J Med 2008;359:1018-1026.
9. Ruf AE, Kremers WK, Chavez LL, Descalzi VI, Podesta LG, Villamil FG. Addition of serum sodium into the MELD score predicts waiting list mortality better than MELD alone. Liver Transpl 2005;11:336-343.
10. Londoño MC, Guevara M, Rimola A, Navasa M, Taurá P, Mas A, et al. Hyponatremia impairs early posttransplantation outcome in patients with cirrhosis undergoing liver transplantation. Gastroenterology 2006;130:1135-1143.
11. Heuman DM, Abou-Assi SG, Habib A, Williams LM, Stravitz RT, Sanyal AJ, et al. Persistent ascites and low serum sodium identify patients with cirrhosis and low MELD scores who are at high risk for early death. Hepatology 2004;40:802-810.
12. Leise MD, Yun BC, Larson JJ, Benson JT, Yang JD, Therneau TM, et al. Effect of the pretransplant serum sodium concentration on outcomes following liver transplantation. Liver Transpl 2014;20:687-697.
13. Liver and Intestine Committee OPTN. Proposal to add serumsodiumto the MELD score (MELD-Na). http://transplantpro.org/wp-content/uploads/2014-06-Liver-Action-Item-Add-Serum-Sodium-to-the-MELD-Score-Draft.pdf. Accessed November 2014.
14. United Network for Organ Sharing/Organ Procurement and Transplantation Network. 3.6: allocation of livers. Accessed November 2014.
15. Lucey MR, Schaubel DE, Guidinger MK, Tome S, Merion RM. Effect of alcoholic liver disease and hepatitis C infection on waiting list and posttransplant mortality and transplant survival benefit. Hepatology 2009;50:400-406.
16. Sharma P, Schaubel DE, Guidinger MK, Merion RM. Effect of pretransplant serum creatinine on the survival benefit of liver transplantation. Liver Transpl 2009;15: 1808-1813.
17. Englesbe MJ, Schaubel DE, Cai S, Guidinger MK, Merion RM. Portal vein thrombosis and liver transplant survival benefit. Liver Transpl 2010;16:999-1005.
18. Schaubel DE, Guidinger MK, Biggins SW, Kalbfleisch JD, Pomfret EA, Sharma P, Merion RM. Survival benefitbased deceased-donor liver allocation. Am J Transplant 2009;9(pt 2):970-981.
19. Angeli P, Wong F, Watson H, Ginès P; for CAPPS Investigators. Hyponatremia in cirrhosis: results of a patient population survey. Hepatology 2006;44:1535-1542.
20. Ginès P, Guevara M. Hyponatremia in cirrhosis: pathogenesis, clinical significance, and management. Hepatology 2008;48:1002-1010.
21. Merion RM, Ashby VB, Wolfe RA, Distant DA, Hulbert-Shearon TE, Metzger RA, et al. Deceased-donor characteristics and the survival benefit of kidney transplantation. JAMA 2005;294:2726-2733.
22. Sharma P, Schaubel DE, Gong Q, Guidinger M, Merion RM. End-stage liver disease candidates at the highest Model for End-Stage Liver Disease scores have higher wait-list mortality than status-1A candidates. Hepatology 2012;55:192-198.
23. Fisher RA, Heuman DM, Harper AM, Behnke MK, Smith AD, Russo MW, et al. Region 11 MELD Na exception prospective study. Ann Hepatol 2012;11:62-67.